UNSPSC 51101604: Meglumine antimonate

This classification denotes an antihelminthic agent with the molecular formula C7H18NO8Sb, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75G4TW236W, chemically known as hydroxy(dioxo)-?5-stibane;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol but generally known as meglumine antimonate, which bears US NIH Compound Identifier 64953. European Medicines Agency schedules Meglumine Antimonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12915MIG.

World Health Organization schedules meglumine antimonate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule meglumine antimonate under HS 29221980 and SITC 51461. SMILES: CNCC(C(C(C(CO)O)O)O)O.O[Sb](=O)=O.

UNSPSC 51101604 Meglumine antimonate (Commodity) covers pharmaceutical active ingredients and finished-dose antimony-based treatments for leishmaniasis and related parasitic infections, though recent state and local procurement under this code shows minimal activity aligned with the nominal product scope. The two recent opportunities posted under this code do not reflect purchases of meglumine antimonate itself; instead, they tag unrelated pharmaceutical procurements — one for broad-spectrum antibiotics (doxycycline and ciprofloxacin) and another for naloxone and drug deactivation systems. State and local health departments, county governments, and special-purpose health districts are the primary issuing bodies soliciting pharmaceuticals through cooperative purchasing vehicles and competitive bidding processes, but the specific commodity appears to see limited direct procurement activity through state and local channels.

Geographic activity is concentrated in Illinois and Florida based on recent postings. The Illinois Department of Public Health awarded a completed pharmaceutical piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for $2,999,999.11 over the contract life (12 months initial plus two renewal years), though the commodities supplied (doxycycline hyclate and ciprofloxacin hydrochloride) fall outside the meglumine antimonate scope. Seminole County, Florida posted an IFB in June 2026 (due July 26, 2023, per the source record) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, also outside the antimonate category. The code shows little recent activity for its stated commodity; pursuits under this UNSPSC should verify that issuing bodies are actually buying meglumine antimonate rather than relying on the code tag alone.